Table 3.

Parameters Extracted from the Meta-Analyses Indicative of Pooled Efficacy of Anti-Inflammatory Agents

Study	Number of Studies Includeda	Effect Size Mean Difference / Response Yes-No	p	95% CI	Heterogeneity
Minocycline
Rosenblat et al, 201843	3	SMD = −0.78	0.005	[−1.33;-0.24]	I2 = 62%
Zheng et al, 201944	2	SMD = −0.81	0.08	[−1.73;0.10]	I2 = 75%
Köhler-Forsberg et al, 201945	2b	SMD = −0.81	0.08	[−1.72;0.10]	I2 = 77%
	3c	SMD = −0.87	0.003	[−1.45;-0.29]	I2 = 63%
Bai et al, 202046	3	SMD = −0.79	0.002	[−1.29;-0.28]	I2 = 53%
Hang et al, 202147	2	RR = 2.83 response rates	0.02	[1.14;6.98]	I2 = 0%
Celecoxib
Faridhosseini et al, 201448	3	SMD = 3.3 (week 4)	0.002	[1.2;5.3]	I2 = 33%
		SMD = 3.43 (week 6)	<0.001	[1.9;4.9]	I2 = 0%
Faridhosseini et al, 201448	3	OR = 6.6 response rates	<0.001	[2.5;17]	I2 = 0%
Faridhosseini et al, 201448	4	OR = 6.6 remission rates	<0.001	[2.7;15.9]	I2 = 0%
Na et al, 201449/ Na et al, 201650	4	WMD = 3.26	<0.001	[1.81;4.71]	I2 = 0%
Na et al, 201449	4	OR = 6.49 response rates	<0.001	[2.89;14.55]	I2 = 0%
Na et al, 201449	4	OR = 6.58 remission rates	<0.001	[2.55;17.00]	I2 = 0%
Köhler et al, 201451	4	SMD = −0.82	<0.001	[−1.17;-0.46]	I2 = 0%
Köhler et al, 201451	3	OR = 6.59 response rates	<0.001	[2.24;19.42]	I2 = 0%
Köhler et al, 201451	4	OR = 7.89 remission rates	<0.001	[2.94;21.17]	I2 = 0%
Köhler-Forsberg et al, 201945	4	SMD = −0.82	<0.001	[−1.17;-0.46]	I2 = 0%
Köhler-Forsberg et al, 201945	4	RR = 1.88 response rates	<0.001	[1.45;2.45]	I2 = 0%
Köhler-Forsberg et al, 201945	4	RR = 4.11 remission rates	<0.001	[1.86;9.11]	I2 = 0%
Bai et al, 202046	4	SMD = −0.76	<0.001	[−1.14;-0.39]	I2 = 0%
Yuan et al, 202052	3	OR = 9.23 response rates	<0.001	[3.07;27.75]	I2 = 0%
Yuan et al, 202052	3	OR = 6.47 remission rates	0.003	[1.88;22.29]	I2 = 0%
Hang et al, 202147	3	RR = 1.55 response rates	<0.001	[1.23;1.95]	I2 = 0%
Omega3 fatty acids
Martins et al, 201253 reanalysis	11d	SMD = 0.242	0.014	[0.048;0.436]	Q = 38.135 p < 0.001
Martins et al, 201253 updated analysis	16d	SMD = 0.363	0.005	[0.120;0.605]	Q = 55.293 p < 0.001
Lin et al, 201254	12	SMD = 0.23	0.01	[0.05;0.42]	I2 = 73%
Grosso et al, 201455	12	SMD = 0.560	0.002	[0.20;0.92]	I2 = 71%
Appleton et al, 201556	25	SMD = −0.30	0.003	[−0.50;-0.10]	I2 = 59%
Appleton et al, 201556	15	OR = 1.39 response rates	0.09	[0.905;2.04]	I2 = 6%
Appleton et al, 201556	6	OR = 1.38 remission rates	0.17	[0.87;2.20]	I2 = 7%
Mocking et al, 201657	13	SMD = 0.398	0.006	[0.114;0.682]	I2 = 73.36
Sarris et al, 201658	11	Hedges’ g = 0.608	0.009	[0.15;1.06]	I2 = 82%
Wei-Hong et al, 201759	3	SMD = 0.63	<0.001	[0.27;1.00]	I2 = 0%
Schefft et al, 201760	10	SMD = −0.48	0.01	[−0.84;-0.11]	I2 = 64%
Bai et al, 202046	12	SMD = −0.35	0.008	[−0.60;-0.09]	I2 = 61%
Luo et al, 202061	9e	SMD = −0.715	Not stated	[−1.13;−0.28]5	I2 = 87.4%
	10f	SMD = 1.2436		[0.060;2.414]6
Jeremiah et al, 202062	9	SMD = −0.91	<0.001	[−1.44;-0.38]	I2 = 80%
Hang et al, 202147	12	RR = 1.10 response rates	0.33	[0.91;1.34]	I2 = 30%
Chambergo-Michilot et al, 202163	2g	Pooled MD = 0.42	n.s.	[−1.44;2.29]	I2 = 35.7%
Chambergo-Michilot et al, 202163	3h	SMD = 0.50	n.s.	[−0.51;1.50]	I2 = 94.1%
Multiple agents
Köhler et al, 201451	5	SMD = −0.54	0.05	[−1.08;-0.01]	I2 = 68%

Notes: ^aStudies included more than once due to multiple arms counting as multiple studies; ^bconsidered as MDD by authors; ^cconsidered as MDD and depressive symptoms, but Emadi-Kouchak et al, 2016 is considered MDD by other authors; ^dlikely studies with multiple arms only counted once/paper does not provide appropriate information; ^eas per results section; ^fas per abstract; ^goutcome HAMD; ^houtcome BDI.

Abbreviations: CI, confidence interval; SMD, standard mean differences; WMD, weighted mean differences; OR, pooled odds ratios; RR, relative risk; pooled MD, pooled mean difference.